Insights

Growth Potential Fusion Antibodies is a small to mid-sized biotechnology contractor focused on antibody discovery and development with a track record of progressing projects to clinical stages, presenting opportunities to upsell expanded discovery, engineering, and developability services to current and former clients seeking faster timelines and higher clinical success.

Strategic Partnerships Recent collaborations and IP transfers with Finn Therapeutics indicate a push toward sustained collaborations and recurring fees; this suggests targeting multi-project partnerships, bundled service packages, and long-term collaboration agreements with existing and potential biotech customers.

Launchpad Momentum InnovateUK Launchpad grant progress on DR5-targeting antibodies highlights capability in funded, high-profile programs; sales plays could emphasize grant-funded projects, scalability of manufacturing-ready lead candidates, and access to early-stage regulatory-ready platforms.

Revenue Uplift Interim revenue fluctuations alongside a full-year revenue uplift signal volatility but potential for upsell through follow-on projects and higher-margin engineering and optimization work; propose hybrid engagement models combining discovery, humanization, affinity maturation, and developability services.

Global Exposure Public listing and UK/EU market presence, plus a Belfast headquarters, position Fusion Antibodies as a regional hub with international client prospects; focus on cross-border opportunities, EU/UK grant-influenced deals, and lead generation among mid-sized Western biotech firms seeking cost-effective, end-to-end antibody programs.

Similar companies to Fusion Antibodies

Fusion Antibodies Tech Stack

Fusion Antibodies uses 8 technology products and services including Demandbase, Linkedin Insight Tag, iCIMS, and more. Explore Fusion Antibodies's tech stack below.

Media & News

Fusion Antibodies's Email Address Formats

Fusion Antibodies uses at least 3 email formats:
Fusion Antibodies Email FormatsExamplePercentage
First.Last@fusionantibodies.comJohn.Doe@fusionantibodies.com
85%
First@fusionantibodies.comJohn@fusionantibodies.com
11%
FLast@fusionantibodies.comJDoe@fusionantibodies.com
4%

Frequently Asked Questions

What is Fusion Antibodies's phone number?

Minus sign iconPlus sign icon
You can contact Fusion Antibodies's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Fusion Antibodies's official website and social media links?

Minus sign iconPlus sign icon
Fusion Antibodies's official website is fusionantibodies.com and has social profiles on LinkedIn.

How much revenue does Fusion Antibodies generate?

Minus sign iconPlus sign icon
As of October 2026, Fusion Antibodies's annual revenue is estimated to be $1M - $10M.

What is Fusion Antibodies's SIC code and NAICS code?

Minus sign iconPlus sign icon
Fusion Antibodies's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Fusion Antibodies have currently?

Minus sign iconPlus sign icon
As of October 2026, Fusion Antibodies has approximately 30 employees across 2 continents, including Europe and North America. Key team members include Chief Executive Officer: A. K., Chief Scientific Officer: R. B. and Chairman: S. D. Explore Fusion Antibodies's employee directory with LeadIQ.

What industry does Fusion Antibodies belong to?

Minus sign iconPlus sign icon
Fusion Antibodies operates in the Biotechnology Research industry.

What technology does Fusion Antibodies use?

Minus sign iconPlus sign icon
Fusion Antibodies's tech stack includes Demandbase, Linkedin Insight Tag, iCIMS, Amazon Web Services, Microsoft SharePoint, WordPress, Piwik PRO Core and DigitalOcean Web Hosting.

What is Fusion Antibodies's email format?

Minus sign iconPlus sign icon
Fusion Antibodies's email format typically follows the pattern of First.Last@fusionantibodies.com. Find more Fusion Antibodies email formats with LeadIQ.

When was Fusion Antibodies founded?

Minus sign iconPlus sign icon
Fusion Antibodies was founded in 2001.
Fusion Antibodies logo

Fusion Antibodies

Biotechnology ResearchNorthern Ireland, United Kingdom11-50 Employees

Fusion Antibodies is a biotechnology research company focused on the discovery, engineering, and supply of antibody-related services for early-stage development. Its work centers on helping clients advance therapeutic antibodies through preclinical stages, with a track record of guiding hundreds of projects and several moving into clinical development. The company emphasizes precision early-stage discovery and employs proprietary platforms for antibody humanization, affinity maturation, and developability optimization to support clients’ research programs and reduce development risk. Based in Belfast, Northern Ireland, Fusion Antibodies operates in the biotechnology research sector and serves customers seeking to accelerate the design and optimization of antibody candidates. The firm has been active since 2001 and maintains a presence as a contract research entity providing discovery, design, and optimisation services for therapeutic antibodies and related applications. A recent development noted in public updates includes collaboration and project progress with external partners and initiatives in antibody targeting and validation programs.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2001
Employees
11-50

Section iconFunding & Financials

  • $1M - $10M

    Fusion Antibodies's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.